OOIR: Observatory of International Research

Papers

(The H4-Index of Blood Reviews is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Not all LGL leukemias are created equal	99
Transplant-acquired allergy in HCT-recipients: Reference for clinical management	69
Pitfalls in laboratory monitoring of treatment in people with Haemophilia	67
Editorial Board	65
Expanding post-transplant cyclophosphamide to matched unrelated donor transplants and beyond	63
Radiation and leukaemia: Which leukaemias and what doses?	63
Practical guidance on the prevention and management of infection in multiple myeloma patients: A case-based approach	62
Clinical burden of hemophilia in older adults: Beyond bleeding risk	62
Beyond current treatment of Fanconi Anemia: What do advances in cell and gene-based approaches offer?	60
Advances in the critical care management for patients with hematological malignancies	59
Artificial intelligence in sickle disease	58
Thalassaemia in China	54
Addressing the challenges of accelerated and blast phase myeloproliferative neoplasms in 2022 and beyond	52
Targeting the neonatal Fc receptor (FcRn) in hematologic conditions with a focus on warm autoimmune hemolytic anemia	46
Artificial intelligence in myeloid malignancies: Clinical applications of machine learning in myelodysplastic syndromes and acute myeloid Leukemia	46
Management of infection in PNH patients treated with eculizumab or other complement inhibitors: Unmet clinical needs	46
Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma	45
Thrombotic events associated with immune checkpoint inhibitors and novel antithrombotic strategies to mitigate bleeding risk	44
Chasing leukemia differentiation through induction therapy, relapse and transplantation	42
Breaking down frailty: Assessing vulnerability in acute myeloid leukemia	42
Failure of CAR-T cell therapy in relapsed and refractory large cell lymphoma and multiple myeloma: An urgent unmet need	42
Corrigendum to “Activation of pyruvate kinase as therapeutic option for rare hemolytic anemias: Shedding new light on an old enzyme” [Blood Rev. 2023 Sep:61:101103]	41
Ph-chromosome-negative myeloproliferative neoplasms: clonal dynamics are the name of the game	38
Adenovirus infection in adult allogeneic hematopoietic stem cell transplant recipients: Systematic review and meta-analysis	38
The landscape of immune monitoring in CAR-T cell therapy: A comprehensive review and survey study by the Cellular Therapy and Immunobiology Working Party of the EBMT	37

BTK inhibitors resistance in B cell malignancies: Mechanisms and potential therapeutic strategies	37
Harnessing multi-source data for individualized care in Hodgkin Lymphoma	35
Gut dysbiosis, endotoxemia and clotting activation: A dangerous trio for portal vein thrombosis in cirrhosis	34
Old tests and new paradigms: How to interpret iron studies and related biomarkers for the diagnosis of iron deficiency in adults	31
Gut microbiome composition and dysbiosis in immune thrombocytopenia: A review of literature	31
Endothelial cells: major players in acute myeloid leukaemia	31